{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:36:04Z","timestamp":1787582164350,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["NO. 15882026XCZX012"],"award-info":[{"award-number":["NO. 15882026XCZX012"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Education and Industry Collaboration in Joint Training Program","award":["220601164154747"],"award-info":[{"award-number":["220601164154747"]}]},{"name":"Education and Industry Collaboration in Joint Training Program","award":["220601164013611"],"award-info":[{"award-number":["220601164013611"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11596-026-00216-6","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:46:48Z","timestamp":1781102808000},"page":"914-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Romiplostim in the Treatment of Aplastic Anemia: A Systematic Review and Single-Arm Meta-Analysis"],"prefix":"10.1007","volume":"46","author":[{"given":"Zhi-xuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-lu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-le","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"17","key":"216_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS. Aplastic Anemia. N Engl J Med. 2018;379(17):1643\u20131656.","journal-title":"N Engl J Med."},{"issue":"4","key":"216_CR2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3324\/haematol.12020","volume":"93","author":"E Montan\u00e9","year":"2008","unstructured":"Montan\u00e9 E, Ib\u00e1\u00f1ez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518\u2013523.","journal-title":"Haematologica."},{"issue":"10","key":"216_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3324\/haematol.2017.169862","volume":"102","author":"K Vaht","year":"2017","unstructured":"Vaht K, G\u00f6ransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica. 2017;102(10):1683\u20131690.","journal-title":"Haematologica."},{"issue":"6","key":"216_CR4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41375-023-01892-2","volume":"37","author":"RP Gale","year":"2023","unstructured":"Gale RP, Hinterberger W, Young NS, et al. What causes aplastic anaemia? Leukemia. 2023;37(6):1191\u20131193.","journal-title":"Leukemia."},{"issue":"5","key":"216_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12185-013-1331-y","volume":"97","author":"SH Shin","year":"2013","unstructured":"Shin SH, Lee JW. The optimal immunosuppressive therapy for aplastic anemia. Int J Hematol. 2013;97(5):564\u2013572.","journal-title":"Int J Hematol."},{"key":"216_CR6","doi-asserted-by":"crossref","unstructured":"Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324(19):1297\u20131304.","DOI":"10.1056\/NEJM199105093241901"},{"issue":"12","key":"216_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-017-0511-z","volume":"18","author":"SA Peslak","year":"2017","unstructured":"Peslak SA, Olson T, Babushok DV. Diagnosis and Treatment of Aplastic Anemia. Curr Treat Options Oncol. 2017;18(12):70.","journal-title":"Curr Treat Options Oncol."},{"issue":"12","key":"216_CR8","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","volume":"123","author":"R Desmond","year":"2014","unstructured":"Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818\u20131825.","journal-title":"Blood."},{"issue":"16","key":"216_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med. 2017;376(16):1540\u20131550.","journal-title":"N Engl J Med."},{"key":"216_CR10","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/DDDT.S299591","volume":"15","author":"JB Bussel","year":"2021","unstructured":"Bussel JB, Soff G, Balduzzi A, et al. A Review of Romiplostim Mechanism of Action and Clinical Applicability. Drug Des Devel Ther. 2021;15:2243\u20132268.","journal-title":"Drug Des Devel Ther."},{"issue":"6","key":"216_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/stem.140678","volume":"14","author":"H Akahori","year":"1996","unstructured":"Akahori H, Shibuya K, Ozai M, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice. Stem Cells. 1996;14(6):678\u2013689.","journal-title":"Stem Cells."},{"issue":"2","key":"216_CR12","first-page":"265","volume":"24","author":"K Kaushansky","year":"1996","unstructured":"Kaushansky K, Lin N, Grossmann A, et al. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol. 1996;24(2):265\u2013269.","journal-title":"Exp Hematol."},{"issue":"25","key":"216_CR13","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2015-09-669929","volume":"127","author":"LV Kovtonyuk","year":"2016","unstructured":"Kovtonyuk LV, Manz MG, Takizawa H. Enhanced thrombopoietin but not G-CSF receptor stimulation induces self-renewing hematopoietic stem cell divisions in vivo. Blood. 2016;127(25):3175\u20133179.","journal-title":"Blood."},{"issue":"12","key":"216_CR14","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI26674","volume":"115","author":"K Kaushansky","year":"2005","unstructured":"Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115(12):3339\u20133347.","journal-title":"J Clin Invest."},{"issue":"1","key":"216_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.stem.2012.10.012","volume":"12","author":"B de Laval","year":"2013","unstructured":"de Laval B, Pawlikowska P, Petit-Cocault L, et al. Thrombopoietin-increased DNA-PK-dependent DNA repair limits hematopoietic stem and progenitor cell mutagenesis in response to DNA damage. Cell Stem Cell. 2013;12(1):37\u201348.","journal-title":"Cell Stem Cell."},{"key":"216_CR16","doi-asserted-by":"crossref","unstructured":"Guenther KL, Cheruku PS, Cash A, et al. Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells. Exp Hematol. 2019;73:1\u20136.e.","DOI":"10.1016\/j.exphem.2019.03.002"},{"issue":"11","key":"216_CR17","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1016\/S2352-3026(19)30153-X","volume":"6","author":"JW Lee","year":"2019","unstructured":"Lee JW, Lee SE, Jung CW, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019;6(11):e562\u2013e572.","journal-title":"Lancet Haematol."},{"issue":"3","key":"216_CR18","first-page":"1061","volume":"111","author":"M Bordbar","year":"2026","unstructured":"Bordbar M, Faghihi A, Zekavat OR, et al. Safety and efficacy of romiplostim in children with acquired aplastic anemia who are naive to immunosuppressive therapy. Haematologica. 2026;111(3):1061\u20131064","journal-title":"Haematologica."},{"issue":"4","key":"216_CR19","volume":"15","author":"G Dhingra","year":"2023","unstructured":"Dhingra G, Rajoreya A. A Single-Centre Experience of First-Line Romiplostim and Immunosuppressive Therapy in Patients With Aplastic Anemia. Cureus. 2023;15(4):e37682.","journal-title":"Cureus."},{"key":"216_CR20","first-page":"386","volume":"4","author":"K Hosokawa","year":"2020","unstructured":"Hosokawa K, Yamazaki H, Tanabe M, et al. High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. HemaSphere. 2020;4:386.","journal-title":"HemaSphere."},{"issue":"6","key":"216_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s12185-020-02971-1","volume":"112","author":"M Ise","year":"2020","unstructured":"Ise M, Iizuka H, Kamoda Y, et al. Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study. Int J Hematol. 2020;112(6):787\u2013794.","journal-title":"Int J Hematol."},{"issue":"1","key":"216_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjh.17190","volume":"192","author":"JH Jang","year":"2021","unstructured":"Jang JH, Tomiyama Y, Miyazaki K, et al. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II\/III, multicentre, open-label study. Br J Haematol. 2021;192(1):190\u2013199.","journal-title":"Br J Haematol."},{"issue":"2","key":"216_CR23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/bjh.20206","volume":"207","author":"JW Lee","year":"2025","unstructured":"Lee JW, Jang JH, Chiba S, et al. Romiplostim with ciclosporin A in patients with aplastic anaemia na\u00efve to immunosuppressive therapy: A phase 2\/3 study. Br J Haematol. 2025;207(2):582\u2013590.","journal-title":"Br J Haematol."},{"issue":"22","key":"216_CR24","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1182\/bloodadvances.2024014855","volume":"9","author":"JW Lee","year":"2025","unstructured":"Lee JW, Jang JH, Yamazaki H, et al. Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia. Blood Adv. 2025;9(22):5732\u20135735.","journal-title":"Blood Adv."},{"issue":"1","key":"216_CR25","doi-asserted-by":"publisher","first-page":"2514791","DOI":"10.1080\/07853890.2025.2514791","volume":"57","author":"X Lin","year":"2025","unstructured":"Lin X, Yang C, Liu Z, et al. Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study. Ann Med. 2025;57(1):2514791.","journal-title":"Ann Med."},{"key":"216_CR26","first-page":"S6","volume":"40","author":"B Madhupriya","year":"2024","unstructured":"Madhupriya B, Ross C, Chaithanya HB, et al. Efficacy of Romiplostim in Newly Diagnosed Aplastic Anaemia. Indian J Hematol Blood Transfus. 2024;40:S6.","journal-title":"Indian J Hematol Blood Transfus."},{"issue":"Suppl 1","key":"216_CR27","doi-asserted-by":"publisher","first-page":"S585","DOI":"10.1016\/S2152-2650(24)01735-X","volume":"24","author":"S Nadjat","year":"2024","unstructured":"Nadjat S. CT-023 Place of Romiplostim in the Treatment of Bone Marrow Aplasia\u2014Experience of the Sidi Bel Abb\u00e8s Hematology Department, Algeria. Clin Lymphoma Myeloma Leuk. 2024;24(Suppl 1):S585.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"1","key":"216_CR28","volume":"17","author":"V Ramanan","year":"2025","unstructured":"Ramanan V, Kelkar K. Romiplostim in Aplastic Anemia: A Single-Center Retrospective Study. Cureus. 2025;17(1):e78228.","journal-title":"Cureus."},{"issue":"2","key":"216_CR29","first-page":"92","volume":"66","author":"S Sato","year":"2025","unstructured":"Sato S, Tsunoda S, Kamata W, et al. Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag. Jpn J Clin Hematol. 2025;66(2):92\u201399.","journal-title":"Jpn J Clin Hematol."},{"issue":"4","key":"216_CR30","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.phoj.2023.10.164","volume":"8","author":"H Tak","year":"2023","unstructured":"Tak H, Trivedi M, Joshi N, et al. Romiplostim and immunosuppressive therapy as first line treatment in patients with aplastic anemia. Pediatr Hematol Oncol J. 2023;8(4):S64.","journal-title":"Pediatr Hematol Oncol J."},{"key":"216_CR31","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1182\/blood-2025-3195","volume":"146","author":"T Wang","year":"2025","unstructured":"Wang T, Li L, Wang H, et al. Efficacy and safety of romiplostim N01 combined with cyclosporine in refractory aplastic anemia patients:a multicenter phase II study. Blood. 2025;146:3195.","journal-title":"Blood."},{"key":"216_CR32","first-page":"1426","volume":"146","author":"L Zhang","year":"2025","unstructured":"Zhang L, Ren X, Hu X, et al. First-line romiplostim combined with immunosuppressive therapy for severe aplastic anemia: A prospective, single-arm, Phase II study. Blood. 2025;146:1426.","journal-title":"Phase II study. Blood."},{"issue":"2","key":"216_CR33","first-page":"177","volume":"47","author":"Q Zhuang","year":"2026","unstructured":"Zhuang Q, Liu Z, Yang C, et al. Efficacy and safety of romiplostim N01 for refractory aplastic anemia: A retrospective single-center study. Zhonghua Xue Ye Xue Za Zhi (Chinese). 2026;47(2):177\u2013181 .","journal-title":"Zhonghua Xue Ye Xue Za Zhi (Chinese)."},{"key":"216_CR34","doi-asserted-by":"crossref","unstructured":"Zhao LP, Sicre De Fontbrune F, Contejean A, et al. Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. Bone Marrow Transplant. 2019;54(7):1161\u20131163.","DOI":"10.1038\/s41409-019-0452-1"},{"issue":"5","key":"216_CR35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/MPH.0000000000002891","volume":"46","author":"A Sharathkumar","year":"2024","unstructured":"Sharathkumar A, Carr J, Claassen D, et al. Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome. J Pediatr Hematol Oncol. 2024;46(5):252\u2013261.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"3","key":"216_CR36","first-page":"794","volume":"111","author":"S Nakao","year":"2026","unstructured":"Nakao S. Romiplostim for aplastic anemia: beyond an eltrombopag alternative. Haematologica. 2026;111(3):794\u2013796.","journal-title":"Haematologica."},{"issue":"2","key":"216_CR37","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s11135-018-0802-x","volume":"53","author":"A Bell","year":"2019","unstructured":"Bell A, Fairbrother M, Jones K. Fixed and random effects models: making an informed choice. Qual Quant. 2019;53(2):1051\u20131074.","journal-title":"Qual Quant."},{"issue":"11","key":"216_CR38","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-14-3379","volume":"75","author":"JA Kim","year":"2015","unstructured":"Kim JA, Shim JS, Lee GY, et al. Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. Cancer Res. 2015;75(11):2222\u20132231.","journal-title":"Cancer Res."},{"issue":"6","key":"216_CR39","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","volume":"76","author":"B Wang","year":"2004","unstructured":"Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76(6):628\u2013638.","journal-title":"Clin Pharmacol Ther."},{"issue":"4","key":"216_CR40","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1208\/s12248-010-9234-9","volume":"12","author":"YM Wang","year":"2010","unstructured":"Wang YM, Krzyzanski W, Doshi S, et al. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. Aaps j. 2010;12(4):729\u2013740.","journal-title":"Aaps j."},{"key":"216_CR41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood.V130.Suppl_1.777.777","volume":"130","author":"T Winkler","year":"2017","unstructured":"Winkler T, Cooper JN, Townsley DM, et al. Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling. Blood. 2017;130:777.","journal-title":"Blood."},{"issue":"12","key":"216_CR42","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3324\/haematol.2016.146746","volume":"101","author":"CA Di Buduo","year":"2016","unstructured":"Di Buduo CA, Currao M, Pecci A, et al. Revealing eltrombopag's promotion of human megakaryopoiesis through AKT\/ERK-dependent pathway activation. Haematologica. 2016;101(12):1479\u20131488.","journal-title":"Haematologica."},{"issue":"12","key":"216_CR43","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3324\/haematol.2016.153668","volume":"101","author":"H Raslova","year":"2016","unstructured":"Raslova H, Vainchenker W, Plo I. Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica. 2016;101(12):1443\u20131445.","journal-title":"Haematologica."},{"key":"216_CR44","doi-asserted-by":"crossref","unstructured":"Zhao Z, Sun Q, Sokoll LJ, et al, Grasmeder S, et al. Eltrombopag mobilizes iron in patients with aplastic anemia. Blood. 2018;131(21):2399\u20132402.","DOI":"10.1182\/blood-2018-01-826784"},{"key":"216_CR45","doi-asserted-by":"crossref","unstructured":"Kao YR, Chen J, Narayanagari SR, et al. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. Sci Transl Med. 2018;10(458).","DOI":"10.1126\/scitranslmed.aas9563"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-026-00216-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-026-00216-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-026-00216-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:54:53Z","timestamp":1787579693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-026-00216-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["216"],"URL":"https:\/\/doi.org\/10.1007\/s11596-026-00216-6","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing financial interests in this study.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval\u00a0and\u00a0Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}